Anebulo Pharmaceuticals (ANEB) Competitors $1.60 +0.03 (+1.91%) Closing price 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.63%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. TRDA, CRVS, PVLA, TSVT, TNXP, ALLO, INZY, ALDX, CADL, and ACBShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Entrada Therapeutics Corvus Pharmaceuticals Palvella Therapeutics 2seventy bio Tonix Pharmaceuticals Allogene Therapeutics Inozyme Pharma Aldeyra Therapeutics Candel Therapeutics Aurora Cannabis Entrada Therapeutics (NASDAQ:TRDA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Which has more risk and volatility, TRDA or ANEB? Entrada Therapeutics has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Does the media refer more to TRDA or ANEB? In the previous week, Entrada Therapeutics had 9 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 10 mentions for Entrada Therapeutics and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 0.34 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Entrada Therapeutics Neutral Anebulo Pharmaceuticals Very Positive Which has preferable earnings and valuation, TRDA or ANEB? Entrada Therapeutics has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.15$65.63M$0.817.88Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-6.15 Do analysts prefer TRDA or ANEB? Entrada Therapeutics currently has a consensus price target of $25.67, suggesting a potential upside of 302.30%. Anebulo Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 243.75%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of TRDA or ANEB? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is TRDA or ANEB more profitable? Entrada Therapeutics has a net margin of 14.39% compared to Anebulo Pharmaceuticals' net margin of 0.00%. Entrada Therapeutics' return on equity of 5.84% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics14.39% 5.84% 4.61% Anebulo Pharmaceuticals N/A -90.11%-84.53% SummaryEntrada Therapeutics beats Anebulo Pharmaceuticals on 14 of the 16 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.50M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-6.1520.3628.1519.68Price / SalesN/A302.56437.63100.28Price / CashN/A42.3835.5357.53Price / Book10.677.768.235.67Net Income-$8.20M-$55.11M$3.23B$257.51M7 Day Performance-8.05%0.95%-0.01%0.52%1 Month Performance1.27%8.44%5.61%8.84%1 Year Performance-33.61%-2.38%26.52%14.18% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.715 of 5 stars$1.60+1.9%$5.50+243.8%-35.1%$64.50MN/A-6.154Positive NewsGap UpTRDAEntrada Therapeutics3.3011 of 5 stars$6.97-3.6%$25.67+268.2%-64.3%$274.40M$172.22M8.61110CRVSCorvus Pharmaceuticals2.8374 of 5 stars$3.90-1.3%$15.00+284.6%+108.5%$269.27MN/A-3.9830Positive NewsPVLAPalvella Therapeutics2.5094 of 5 stars$24.90+3.2%$46.29+85.9%N/A$266.66M$42.81M-2.06N/ATSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440TNXPTonix Pharmaceuticals2.662 of 5 stars$35.44-0.1%$585.00+1,550.7%-25.9%$261.03M$10.04M-0.0250ALLOAllogene Therapeutics3.6513 of 5 stars$1.16-2.5%$8.44+628.0%-58.4%$260.29M$20K-0.94310Positive NewsINZYInozyme Pharma3.4875 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750Positive NewsALDXAldeyra Therapeutics2.5715 of 5 stars$4.35+1.2%$9.50+118.4%+25.5%$257.55MN/A-4.4810News CoveragePositive NewsCADLCandel Therapeutics2.4772 of 5 stars$4.99-2.2%$22.00+340.9%-5.6%$255.53MN/A-3.7260Positive NewsAnalyst RevisionACBAurora Cannabis0.36 of 5 stars$4.43-2.4%N/A-26.3%$255.21M$246.72M40.271,130 Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Palvella Therapeutics Alternatives 2seventy bio Alternatives Tonix Pharmaceuticals Alternatives Allogene Therapeutics Alternatives Inozyme Pharma Alternatives Aldeyra Therapeutics Alternatives Candel Therapeutics Alternatives Aurora Cannabis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
